The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction

被引:143
作者
Yip, G. W. K. [1 ]
Wang, M. [1 ]
Wang, T. [1 ]
Chan, S. [1 ]
Fung, J. W. H. [1 ]
Yeung, L. [1 ]
Yip, T. [2 ]
Lau, S-T [3 ]
Lau, C-P [4 ]
Tang, M-O [4 ]
Yu, C-M [1 ]
Sanderson, J. E. [1 ]
机构
[1] Chinese Univ Hong Kong, Div Cardiol, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China
[2] Yan Chai Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[3] Princess Margaret Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[4] Univ Hong Kong, Queen Mary Hosp, Div Cardiol, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1136/hrt.2007.117978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although heart failure with a preserved or normal ejection fraction (HFNEF or diastolic heart failure) is common, treatment outcomes on quality of life and cardiac function are lacking. The effect of renin angiotensin blockade by irbesartan or ramipril in combination with diuretics on quality of life (QoL), regional and global systolic and diastolic function was assessed in HFNEF patients. Methods: 150 patients with HFNEF (LVEF > 45%) were randomised to (1) diuretics alone, (2) diuretics plus irbesartan, or (3) diuretics plus ramipril. QoL, 6-minute walk test (6MWT) and Doppler echocardiography were performed at baseline, 12, 24 and 52 weeks. Results: The QoL score improved similarly in all three groups by 52 weeks (-46%, 51%, and 50% respectively, all p < 0.01), although 6MWT increased only slightly (average +3-6%). Recurrent hospitalisation rates were equal in all groups (10-12% in 1 year). At 1 year, LV dimensions or LVEF had not changed in any group, though both systolic and diastolic blood pressures were lowered in all three groups from 4 weeks onwards. At baseline both mean peak systolic (Sm) and early diastolic (Em) mitral annulus velocities were reduced, and increased slightly in the diuretic plus irbesartan (Sm 4.5 (SEM 0.17) to 4.9 (SEM 0.16) cm/sec; Em 3.8 (SEM 0.25) to 4.2 (SEM 0.25) cm/sec) and ramipril (Sm 4.5 (SEM 0.24) to 4.9 (SEM 0.20) cm/sec; Em 3.3 (SEM 0.25) to 4.04 (SEM 0.32) cm/sec) groups (both p < 0.05). NT-pro-BNP levels were raised at baseline ( 595 (SD 905) pg/ml; range 5 4748) and fell in the irbesartan (-124 (SD 302) pg/ml, p=0.01) and ramipril (-173 (SD 415) pg/ml, p=0.03) groups only. Conclusions: In this typically elderly group of HF patients with normal LVEF, diuretic therapy significantly improved symptoms and neither irbesartan nor ramipril had a significant additional effect. However, diuretics in combination with irbesartan or ramipril marginally improved LV systolic and diastolic longitudinal LV function, and lowered NT-proBNP over 1 year.
引用
收藏
页码:573 / 580
页数:8
相关论文
共 40 条
  • [1] Comparison of quality of life measures in heart failure
    Bennett, SJ
    Oldridge, NB
    Eckert, GJ
    Embree, JL
    Browning, S
    Hou, N
    Chui, M
    Deer, M
    Murray, MD
    [J]. NURSING RESEARCH, 2003, 52 (04) : 207 - 216
  • [2] Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease
    Brilla, CG
    Funck, RC
    Rupp, H
    [J]. CIRCULATION, 2000, 102 (12) : 1388 - 1393
  • [3] Doppler tissue analysis of mitral annular velocities: Evidence for systolic abnormalities in patients with diastolic heart failure
    Bruch, C
    Gradaus, R
    Gunia, S
    Breithardt, G
    Wichter, T
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2003, 16 (10) : 1031 - 1036
  • [4] Atrioventricular plane displacement is the major contributor to left ventricular pumping in healthy adults, athletes, and patients with dilated cardiomyopathy
    Carlsson, Marcus
    Ugander, Martin
    Mosen, Henrik
    Buhre, Torsten
    Arheden, Hakan
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2007, 292 (03): : H1452 - H1459
  • [5] The perindopril in elderly people with chronic heart failure (PEP-CHF) study
    Cleland, John G. F.
    Tendera, Michal
    Adamus, Jerzy
    Freemantle, Nick
    Polonski, Lech
    Taylor, Jacqueline
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (19) : 2338 - 2345
  • [6] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    Devereux, RB
    Dahlöf, B
    Gerdts, E
    Boman, K
    Nieminen, MS
    Papademetriou, V
    Rokkedal, J
    Harris, KE
    Edelman, JM
    Wachtell, K
    [J]. CIRCULATION, 2004, 110 (11) : 1456 - 1462
  • [7] ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT-VENTRICULAR HYPERTROPHY - COMPARISON TO NECROPSY FINDINGS
    DEVEREUX, RB
    ALONSO, DR
    LUTAS, EM
    GOTTLIEB, GJ
    CAMPO, E
    SACHS, I
    REICHEK, N
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1986, 57 (06) : 450 - 458
  • [8] Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients
    Díez, J
    Querejeta, R
    López, B
    González, A
    Larman, M
    Ubago, JLM
    [J]. CIRCULATION, 2002, 105 (21) : 2512 - 2517
  • [9] Optimal noninvasive assessment of left ventricular filling pressures - A comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters
    Dokainish, H
    Zoghbi, WA
    Lakkis, NM
    Al-Bakshy, F
    Dhir, M
    Quinones, MA
    Nagueh, SF
    [J]. CIRCULATION, 2004, 109 (20) : 2432 - 2439
  • [10] Reduced systolic performance by tissue Doppler in patients with preserved and abnormal ejection fraction:: New insights in chronic heart failure
    García, EH
    Perna, ER
    Farías, EF
    Obregón, RO
    Macin, SM
    Parras, JI
    Agüero, MA
    Moratorio, DA
    Pitzus, AE
    Tassano, EA
    Rodriguez, L
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 108 (02) : 181 - 188